+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver Diseases Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 194 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309912
The global market for Liver Diseases Treatment is estimated at US$18.9 Billion in 2023 and is projected to reach US$37.9 Billion by 2030, growing at a CAGR of 10.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Anti-Rejection Drugs/Immunosupressants segment, which is expected to reach US$6.3 Billion by 2030 with a CAGR of a 10.9%. The Chemotherapy Drugs segment is also set to grow at 11.6% CAGR over the next 7 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $4.9 Billion in 2023, and China, forecasted to grow at an impressive 13.7% CAGR to reach $8.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Liver Diseases Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Liver Diseases Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Liver Diseases Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 41 Featured):

  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Pvt., Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Liver Diseases Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Global Economic Update
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Liver Diseases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Liver Diseases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Liver Diseases Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Anti-Rejection Drugs/Immunosupressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Anti-Rejection Drugs/Immunosupressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Anti-Rejection Drugs/Immunosupressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Chemotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Chemotherapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Chemotherapy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Targeted therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Targeted therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 12: World 16-Year Perspective for Targeted therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 15: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Anti-Viral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 17: World Historic Review for Anti-Viral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 18: World 16-Year Perspective for Anti-Viral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Iimmunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 20: World Historic Review for Iimmunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 21: World 16-Year Perspective for Iimmunoglobulins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 23: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 24: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 25: World Liver Diseases Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 26: USA Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: USA Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: USA 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
CANADA
  • Table 29: Canada Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: Canada 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
JAPAN
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 32: Japan Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: Japan 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
CHINA
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 35: China Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: China Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: China 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
EUROPE
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 38: Europe Recent Past, Current & Future Analysis for Liver Diseases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 39: Europe Historic Review for Liver Diseases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Europe 16-Year Perspective for Liver Diseases Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 41: Europe Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Europe Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Europe 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
FRANCE
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 44: France Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: France Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: France 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
GERMANY
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 47: Germany Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Germany Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Germany 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
ITALY
  • Table 50: Italy Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Italy Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Italy 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 53: UK Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: UK Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: UK 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
SPAIN
  • Table 56: Spain Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Spain Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Spain 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
RUSSIA
  • Table 59: Russia Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Russia Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Russia 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 62: Rest of Europe Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Rest of Europe Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Rest of Europe 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 65: Asia-Pacific Recent Past, Current & Future Analysis for Liver Diseases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 66: Asia-Pacific Historic Review for Liver Diseases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: Asia-Pacific 16-Year Perspective for Liver Diseases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 68: Asia-Pacific Recent Past, Current & Future Analysis for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: Asia-Pacific Historic Review for Liver Diseases Treatment by Treatment Type - Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 70: Asia-Pacific 16-Year Perspective for Liver Diseases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Iimmunoglobulins and Corticosteroids for the Years 2014, 2024 & 2030
AUSTRALIA
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Liver Diseases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Pvt., Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA

Table Information